StreetInsider.com News Articles

Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'

Tue, 01 Sep 2026 06:33:26 -0400

(Updated - September 1, 2026 6:33 AM EDT)

Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Underweight with a price target of $2.00 (from $5.45).

The analyst comments "We're downgrading MYGN to Underweight from Overweight. We do not believe the current business model can grow or cut its way to profitability, leaving divestiture of assets as the most credible path to value. The company ran a strategic review in 1Q25 and elected to not divest or sell assets, which we read as limited strategic interest in several of its business segments at sufficient valuations. The 2Q26 print

Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'

Tue, 01 Sep 2026 06:33:26 -0400

(Updated - September 1, 2026 6:33 AM EDT)

Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Underweight with a price target of $2.00 (from $5.45).

Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'

Tue, 01 Sep 2026 06:33:26 -0400

(Updated - September 1, 2026 6:33 AM EDT)

Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Underweight with a price target of $2.00 (from $5.45).

Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'

Tue, 01 Sep 2026 06:33:26 -0400

(Updated - September 1, 2026 6:33 AM EDT)

Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Underweight with a price target of $2.00 (from $5.45).

Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'

Tue, 01 Sep 2026 06:33:26 -0400

(Updated - September 1, 2026 6:33 AM EDT)

Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Underweight with a price target of $2.00 (from $5.45).

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 09:05:00 -0400

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST.

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 09:05:00 -0400

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 09:05:00 -0400

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 09:05:00 -0400

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all.

Myriad Genetics (MYGN) PT Lowered to $2.50 at Jefferies

Thu, 20 Aug 2026 15:55:58 -0400

Jefferies analyst Brandon Couillard lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $2.50 (from $4.00) while maintaining a Underperform rating.

Myriad Genetics (MYGN) PT Lowered to $3 at Stephens

Tue, 18 Aug 2026 06:31:24 -0400

Stephens analyst Mason Carrico lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $3.00 (from $5.00) while maintaining a Equal Weight rating.

Form 4 MYRIAD GENETICS INC For: Aug 16 Filed by: Wheeler Benjamin Richard

Mon, 17 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260817/26938277.html

Form 4 MYRIAD GENETICS INC For: Aug 16 Filed by: Wheeler Benjamin Richard

Mon, 17 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260817/26938277.html

Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26932395.html

Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26932395.html

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930604.html

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930604.html

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26888841.html

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26888841.html

Myriad Genetics (MYGN) PT Lowered to $3 at Wells Fargo

Mon, 03 Aug 2026 07:08:46 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $3.00 (from $5.50) while maintaining a Equal Weight rating.

Myriad Genetics (MYGN) PT Lowered to $4 at TD Cowen

Fri, 31 Jul 2026 09:09:51 -0400

TD Cowen analyst Kyle Boucher lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $4.00 (from $6.00) while maintaining a Hold rating.

Form 10-Q MYRIAD GENETICS INC For: Jun 30

Fri, 31 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26847015.html

Form 10-Q MYRIAD GENETICS INC For: Jun 30

Fri, 31 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26847015.html

Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance

Fri, 31 Jul 2026 01:08:44 -0400

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance

Fri, 31 Jul 2026 01:08:44 -0400

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.